Rep. Lisa C. McClain Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Shares

Key Points

• Representative Lisa C. McClain sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP), disclosing a transaction between $1,001 and $15,000 on August 4th, 2025.
• The company's stock dropped by 1.1%, opening at $490.77, with a market cap of $13.79 billion and a PE ratio of 36.49.
• Analysts have mixed opinions on Medpace, with ratings ranging from Buy to Sell and an average price target of $422.27.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Medpace Holdings, Inc. NASDAQ: MEDP. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $4.11 during trading on Thursday, reaching $501.94. The stock had a trading volume of 267,784 shares, compared to its average volume of 439,529. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $506.55. The stock has a market cap of $14.10 billion, a PE ratio of 37.32, a P/E/G ratio of 3.09 and a beta of 1.44. The firm's 50 day moving average price is $439.91 and its two-hundred day moving average price is $352.60.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the business earned $2.75 EPS. The business's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Barclays boosted their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Mizuho boosted their price objective on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Robert W. Baird boosted their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Truist Financial boosted their price objective on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Finally, Rothschild Redb lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average price target of $422.27.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after acquiring an additional 102,015 shares during the period. Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. raised its stake in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock worth $256,559,000 after buying an additional 121,213 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company's stock worth $193,269,000 after buying an additional 81,637 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Medpace by 1.1% in the 1st quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock worth $177,411,000 after buying an additional 6,225 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.